Real|World Characteristics of Patients with Severe Asthma prior to ...

Real-World Characteristics of Patients with Severe Asthma prior to ...

This study describes the characteristics of patients with severe asthma before dupilumab treatment in a real-world setting.

Real-World Characteristics of Patients with Severe Asthma prior to ...

22.3%) and/or clinical remission (37.6% vs. 17.2%) were higher in group B than in group A. Conclusion: Despite more severe asthma at baseline, ...

Real-world characteristics and disease burden of patients with asthma

Allergic rhinitis, atopic dermatitis, and chronic idiopathic urticaria were more common among patients prescribed omalizumab vs mepolizumab. In ...

Characteristics of severe asthma patients on biologics: a real-life ...

Characteristics of severe asthma patients in European countries included in SHARP Central Registry ; Chronic rhinosinusitis, 78 (73.6), 43 (89.6) ; Nasal polyps ...

Characteristics of Severe Asthma Patients and Predictors of Asthma ...

The majority of patients were overweight or obese (BMI 25–29.99 kg/m2, 34.9%, BMI ≥30 kg/m2, 27.7%) and only a small proportion of 2.5% was ...

Baseline characteristics of patients with asthma and prior systemic ...

RAPID (NCT04287621) is a global, prospective registry that aims to characterize patients with asthma initiating dupilumab in real-world clinical practice.

Real-World Assessment of Asthma Specialist Visits Among U.S. ...

U.S. guidelines recommend that patients with severe asthma be referred to specialists (allergists/immunologists or pulmonologists) for ...

Real-World Assessment of Asthma Specialist Visits Among U.S. ...

Of 54,332 patients identified, 38.2% had 1 or more specialist visits over 2 years. Patient characteristics predictive of specialist visits were asthma ...

Biologics in severe asthma: the role of real-world evidence from ...

It is characterised by variable expiratory airflow limitation and chronic airway inflammation, leading to respiratory symptoms such as dyspnoea, wheezing, chest ...

In a Real-World Study, Most Patients with Severe Asthma Had Good ...

Responders were more likely to be male and to have better baseline lung function, higher levels of type 2 markers of inflammation (i.e., ...

Characterisation of patients with severe asthma in the ... - Thorax BMJ

T2-low patients had higher body mass index (32.1 vs 30.2, p<0.001), depression/anxiety prevalence (12.3% vs 7.6%, p=0.04) and mOCS use (57.9% vs 42.1%, p<0.001) ...

THE ZEPHYR-4 STUDY - Annals of Allergy, Asthma & Immunology

HETEROGENEOUS CHARACTERISTICS OF SEVERE ASTHMA PATIENTS INITIATING BENRALIZUMAB IN A REAL-WORLD SETTING: THE ZEPHYR-4 STUDY ; D. · Carstens · Wilmington, DE ; D.

Characterization of Severe Asthma Worldwide - ScienceDirect.com

Patients were predominantly female (59.3%) and white (72.6%), had never smoked (60.5%), and were overweight or obese (70.4%); 34.9% were at GINA Step 5; and ...

Clinical Characteristics and Disease Burden of Severe Asthma ...

... asthmatics shows that chronic use (6 months or more in one year before ... clinical characteristics, and management of severe asthma by obtaining real-world data ...

Biologic treatment eligibility for real-world patients with severe asthma

For severe asthma, phenotypes are heterogeneous with respect to clinical characteristics, physiological measures and biomarker expression ...

Full article: Clinical characteristics and burden of illness among ...

Approximately 10% of patients with asthma have severe disease (Global Initiative for Asthma [GINA] Step 4 or 5), characterized by frequent exacerbations and ...

Real-World Effectiveness of Biologics in Patients With Severe Asthma

Information from these patients was used to compare the effects before and after biologic treatment. ... Clinical characteristics and disease ...

Achieving clinical outcomes with benralizumab in severe ...

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study. Alicia Padilla ...

Real-World Effectiveness of Mepolizumab in Severe Asthma

The Nucala Effectiveness Study (NEST) assessed the effectiveness of mepolizumab in patients with severe asthma (SA) in countries previously ...

Severe asthma exacerbations in the United States

Patients with severe asthma (SA) have a heightened risk of exacerbations including hospitalization. The real-world, specialist-verified incidence and ...